---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-021339"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-06-27T23:59:59+00:00"
generated_at: "2026-06-01T01:00:19.243248+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex begins treating patients in two new lung cancer trials, continues third

## Summary
- Opened enrollment and began treating patients in two new lung cancer clinical trials in 2024.
- Continues treating patients in a third lung cancer clinical trial.
- Partnered with community-based oncology practices to broaden clinical study reach.
- Expanded preclinical programs into new indications; presented positive data at major cancer conference.
- Strengthened global IP estate for lead drug candidate.

## SEC filing metadata
- accession: 0001437749-24-021339
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924021339/0001437749-24-021339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924021339/gnpx20240507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-021339
- JSON: https://secwatch.observer/filing/0001437749-24-021339.json
- Plain text: https://secwatch.observer/filing/0001437749-24-021339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.